Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
E3LΔ83N-TK + hFlt3L + anti-muCTLA-4
- Development stage
- Preclinical
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intratumoral
01
Overview
E3LΔ83N-TK + hFlt3L + anti-muCTLA-4 is an experimental oncolytic virus-based immunotherapy regimen. It utilizes a modified Western Reserve strain of the vaccinia virus, specifically the E3LΔ83N-TK− mutant, which is attenuated through a deletion in the Z-DNA-binding domain of the E3L gene and the thymidine kinase (TK) gene. This viral vector is engineered to express two therapeutic payloads: human FMS-like tyrosine kinase 3 ligand (hFlt3L), which promotes the expansion and activation of dendritic cells, and a murine anti-CTLA-4 antibody (anti-muCTLA-4), which blocks the CTLA-4 immune checkpoint to enhance T-cell mediated anti-tumor responses. Developed by researchers at Memorial Sloan Kettering Cancer Center, this combination is designed for intratumoral delivery to stimulate both local and systemic (abscopal) anti-tumor immunity in solid tumors such as melanoma.
- Other names
- oncolytic vaccinia virus expressing anti-CTLA-4 and hFlt3L
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on E3LΔ83N-TK + hFlt3L + anti-muCTLA-4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on E3LΔ83N-TK + hFlt3L + anti-muCTLA-4.